Ocular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Key Points

• Ocular Therapeutix reported Q1 EPS of ($0.40), missing estimates by $0.08 and posting revenue of $10.79M vs. $12.72M expected, while holding about $667M in cash that management says provides runway into 2028; the stock fell roughly 4.4% intraday.
• AXPAXLI demonstrated statistical superiority to aflibercept in SOL‑1 (P=0.0006) with about two‑thirds of patients maintaining vision after a single injection for a year and a reassuring safety profile, and SOL‑R exceeded enrollment targets with top‑line now guided to Q1 2027 while SOL‑X has begun enrollment.
• Management plans to pursue an NDA relying on SOL‑1 week‑52 data via the 505(b)(2) pathway (FDA discussions ongoing); insider activity included a director purchasing 60,229 shares and analysts' average target is $23.78 (Moderate Buy).

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08), FiscalAI reports. The company had revenue of $10.79 million during the quarter, compared to analyst estimates of $12.72 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The company's quarterly revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.38) EPS.

Here are the key takeaways from Ocular Therapeutix's conference call:

• AXPAXLI demonstrated statistical superiority to aflibercept in SOL-1 (primary endpoint P=0.0006) with unmatched durability—about two-thirds of patients maintained vision after a single injection for a year.
• The company reported a reassuring safety profile for AXPAXLI in SOL-1, with no treatment-related serious ocular or systemic adverse events (e.g., endophthalmitis or vasculitis) observed in presented subject-level data.
• SOL-R exceeded enrollment expectations (631 randomized vs. 555 target) with top-line now guided to Q1 2027, and SOL-X (a 3-year open-label extension) has begun enrollment to evaluate long-term outcomes and crossover effects.
• Ocular plans to submit an NDA relying on SOL-1 week‑52 data and to use the 505(b)(2) pathway, but formal discussions with the FDA are ongoing and could affect timing or data requirements.
• The company ended Q1 with approximately $667 million in cash, providing runway into 2028 to support trials, NDA activities, and commercial readiness, although this figure does not include the full anticipated commercialization expenses.

Ocular Therapeutix Stock Down 4.4%

NASDAQ:OCUL traded down $0.43 during mid-day trading on Tuesday, hitting $9.34. The stock had a trading volume of 639,699 shares, compared to its average volume of 5,384,710. Ocular Therapeutix has a twelve month low of $6.23 and a twelve month high of $16.44. The stock has a 50-day simple moving average of $9.00 and a two-hundred day simple moving average of $10.56. The company has a current ratio of 15.39, a quick ratio of 15.32 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $2.03 billion, a PE ratio of -6.50 and a beta of 0.93.

Insider Activity at Ocular Therapeutix

In other news, Director Richard L. Md Lindstrom acquired 60,229 shares of the company's stock in a transaction on Friday, February 20th. The shares were bought at an average cost of $7.66 per share, with a total value of $461,354.14. Following the transaction, the director owned 246,933 shares in the company, valued at approximately $1,891,506.78. This trade represents a 32.26% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sanjay Nayak sold 10,348 shares of the firm's stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $93,545.92. Following the completion of the sale, the insider owned 332,412 shares in the company, valued at $3,005,004.48. The trade was a 3.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 191,766 shares of company stock worth $1,704,946 over the last ninety days. 2.30% of the stock is currently owned by insiders.

Institutional Trading of Ocular Therapeutix

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Ocular Therapeutix by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company's stock worth $686,000 after acquiring an additional 5,156 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Ocular Therapeutix during the 1st quarter worth about $248,000. Creative Planning lifted its stake in Ocular Therapeutix by 21.5% during the second quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company's stock worth $199,000 after purchasing an additional 3,791 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Ocular Therapeutix by 110.8% during the second quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company's stock worth $6,608,000 after purchasing an additional 374,269 shares during the last quarter. Finally, Prudential Financial Inc. boosted its holdings in Ocular Therapeutix by 57.9% in the second quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company's stock valued at $174,000 after purchasing an additional 6,855 shares in the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of Ocular Therapeutix in a report on Monday, April 13th. Royal Bank Of Canada reissued an "outperform" rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research report on Thursday, February 5th. William Blair restated an "outperform" rating on shares of Ocular Therapeutix in a research note on Monday, March 2nd. Citigroup restated an "outperform" rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.